- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
42 result(s) found for: Human cytomegalovirus.
Displaying page 2 of 3.
EudraCT Number: 2020-004698-30 | Sponsor Protocol Number: 2020-42 | Start Date*: 2021-06-30 |
Sponsor Name: CHU de Lille | ||
Full Title: Efficacy and Safety of Cytotect®CP, hyperimmune anti-CMV IVIg as CMV prophylaxis in patients developing acute grade II-IV GVHD after allogeneic hematopoietic cell transplantation A prospective phas... | ||
Medical condition: Post-transplant human cytomegalovirus (CMV) infection is a challenge in patients receiving allogeneic hematopoietic cell transplants (allo-HCT) due to severe immunosuppression. In the absence of t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006563-23 | Sponsor Protocol Number: CMVfluvaccinees | Start Date*: 2007-02-07 | |||||||||||
Sponsor Name:Health Protection Agency | |||||||||||||
Full Title: A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged... | |||||||||||||
Medical condition: The vaccine is designed to provide protection against circulating influenza and is being used in the UK influnza immunisation programme 2006-7 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000252-28 | Sponsor Protocol Number: SHCVOLT1 | Start Date*: 2009-03-13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004279-15 | Sponsor Protocol Number: TAK-620-2004 | Start Date*: 2022-09-02 | ||||||||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | ||||||||||||||||||
Full Title: A Phase 3, open-label, single-arm, repeated-dose study to evaluate the safety and tolerability, pharmacokinetics, and antiviral activity of maribavir for the treatment of cytomegalovirus (CMV) in... | ||||||||||||||||||
Medical condition: Cytomegalovirus (CMV) infection in children and adolescents who have received a hematopoietic stem cell transplant (HSCT) or a solid organ transplant (SOT) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Trial now transitioned) DE (Trial now transitioned) Outside EU/EEA FR (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013917-91 | Sponsor Protocol Number: AIC246-01-II-02 | Start Date*: 2010-02-09 |
Sponsor Name:AiCuris GmbH & Co. KG | ||
Full Title: A randomized, double-blind, placebo controlled trial to evaluate the safety, tolerability and antiviral activity of 12 weeks’ treatment with a new antiviral HCMV drug | ||
Medical condition: Prevention of active human cytomegalovirus (HCMV) replication by re-infection or re-activation in HCMV seropositive patients after human blood precursor cell (HBPC) transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000485-36 | Sponsor Protocol Number: G0500705 | Start Date*: 2006-08-23 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust | ||
Full Title: A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation | ||
Medical condition: Post Lung Transplantation Chronic Rejection identified as bronchiolitis obliterans syndrome (BOS) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006148-69 | Sponsor Protocol Number: AIC001-2-001 | Start Date*: 2007-03-06 |
Sponsor Name:AiCuris GmbH & Co. KG | ||
Full Title: Phase 2a Randomized, Controlled, Multi-center, Open-label Dose Ranging Proof of Concept Study to Evaluate the Safety, Tolerability and Antiviral Activity of AIC-001 Over 14 Days of Dosing in Patien... | ||
Medical condition: Pre-emptive treatment for Human cytomegalovirus (HCMV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003877-87 | Sponsor Protocol Number: SCGAM-01 | Start Date*: 2014-03-12 |
Sponsor Name:Octapharma Pharmazeutika Prod.Ges.m.b.H | ||
Full Title: CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES | ||
Medical condition: Primary immunodeficiency | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) PL (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004725-13 | Sponsor Protocol Number: SHP620-303 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Shire ViroPharma Incorporated | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients... | ||||||||||||||||||
Medical condition: CMV infections resistant or refractory in transplant patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) ES (Completed) FR (Completed) AT (Completed) HR (Completed) IT (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004734-37 | Sponsor Protocol Number: NORM-01 | Start Date*: 2021-12-14 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Prod.Ges.m.b.H | |||||||||||||
Full Title: Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with p... | |||||||||||||
Medical condition: Primary Immunodeficiency Diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000722-26 | Sponsor Protocol Number: AVM-003-HC | Start Date*: 2021-01-11 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Trans... | |||||||||||||
Medical condition: Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000441-38 | Sponsor Protocol Number: CPCRA 065 | Start Date*: 2005-04-26 |
Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health | ||
Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study) | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004953-26 | Sponsor Protocol Number: BHS-TC13 | Start Date*: 2016-03-11 |
Sponsor Name:Ghent University Hospital | ||
Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020464-38 | Sponsor Protocol Number: PRENU | Start Date*: 2010-06-08 |
Sponsor Name:University of Oslo | ||
Full Title: Nutrition, growth and development among very preterm infants | ||
Medical condition: The main purpose of this study is to evaluate the effect of increased supply of energy, protein, vitamin A and the long chain polyunsaturated fatty acids DHA and AA to Very Low Birth Weight Infants... | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003014-28 | Sponsor Protocol Number: FARM12JCXN | Start Date*: 2017-10-30 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: MULTICENTER RANDOMIZED STUDY ON THE EFFICACY OF IMMUNOSUPPRESSION IN PATIENTS WITH VIRUS-NEGATIVE INFLAMMATORY CARDIOMYOPATHY | |||||||||||||
Medical condition: virus negative inflammatory cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000679-16 | Sponsor Protocol Number: EORTC 06023 | Start Date*: 2005-05-17 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia | |||||||||||||
Medical condition: myelodysplastic syndrome (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003204-39 | Sponsor Protocol Number: BT–L-CsA–301–SLT | Start Date*: 2019-01-09 |
Sponsor Name:BREATH Therapeutics Inc. | ||
Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA... | ||
Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Single Lung Transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003241-89 | Sponsor Protocol Number: LCP-Tacro 3002 | Start Date*: 2010-11-05 | |||||||||||
Sponsor Name:LifeCycle Pharma A/S | |||||||||||||
Full Title: A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study of the Efficacy and Safety of LCP-Tacro™ Tablets, Once Daily, Compared to Prograf® Capsules, Twice Daily, in Combi... | |||||||||||||
Medical condition: Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) SE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003205-25 | Sponsor Protocol Number: BT–L-CsA–302–DLT | Start Date*: 2019-01-09 |
Sponsor Name:BREATH Therapeutics Inc. | ||
Full Title: A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PA... | ||
Medical condition: Bronchiolitis Obliterans Syndrome in Patients post Double Lung Transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) AT (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003450-22 | Sponsor Protocol Number: P-105-303 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar... | |||||||||||||
Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
